Injectable Treatments Articles & Analysis
30 news found
Asclera (Polidocanol) is another notable example, incorporating an m-PEG9 entity that can function as a local anesthetic in topical ointments or as an injectable treatment for varicose veins, showcasing the versatility of PEGylated formulations. ...
By developing innovative liquid and semi-solid formulations, CD Formulation aims to provide pharmaceutical research institutions with more convenient and effective treatment options. CD Formulation's injectable formulation platform is another key technology that the company offers. Injectable formulations are crucial for delivering drugs that ...
Submission to the Ministry of Health, Labor, and Welfare (MHLW) in Japan for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of phase III clinical trials, PULSAR and PHOTON In both trials, aflibercept 8 mg demonstrated unprecedented durability results with treatment intervals of up to ...
ByBayer AG
Filing for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of clinical trials, PULSAR and PHOTON In both trials, aflibercept 8 mg demonstrated unprecedented durability results with treatment intervals of up to 16 weeks, with comparable visual acuity as well as rapid and resilient fluid ...
ByBayer AG
Food and Drug Administration (FDA) approved a label expansion for OXLUMO® (lumasiran), an RNAi therapeutic administered via subcutaneous injection, now indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate (UOx) and plasma oxalate (POx) levels in pediatric and adult patients. ...
Types of Spinal Injections Spinal injections are also known as lumbar epidural injections, and these can provide incredible pain relief for up to six months following treatment. Here are some of the most common spinal injections for back pain sufferers: Epidural steroid injections This common ...
Other less frequent adverse reactions reported with AMVUTTRA were dyspnea (shortness of breath), injection site reaction and an increase in blood alkaline phosphatase (a liver enzyme). Vutrisiran was previously granted Orphan Drug Designation in the European Union (EU) and U.S. for the treatment of ATTR amyloidosis and in Japan for transthyretin type familial ...
About XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use is a proprietary suspension of the corticosteroid triamcinolone acetonide for administration to the suprachoroidal space for the treatment of macular edema associated with ...
Analyses also showed a positive immunological response to the treatment and the clinical course appears promising with all individuals remaining insulin-independent 12 months after treatment. ...
Government to develop yet another one of the critically important emergency treatment products” said the company founder and CEO, Amir Genosar. ...
A new study with TikoMed’s platform lead clinical drug candidate ILB®, provides positive safety and tolerability results and the first clinical evidence of encouraging clinical efficacy of ILB® in the treatment of Amyotrophic Lateral Sclerosis (ALS). The study was published in PLOS ONE today. ...
“Patients with advanced retinovascular diseases, including DME, shoulder a significant burden with current standard-of-care that usually requires regular doctor visits for frequent injections of anti-VEGF treatment, often as frequently as every 8 weeks,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “Given the encouraging activity ...
(Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced biomarker data from the KALM-1 and KALM-2 clinical trials evaluating KORSUVA™ (difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus ...
(TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, has received a grant from the Israel Innovation Authority (IIA) for a total budget of NIS 10 million ($3.1 million) and a net grant of NIS 4 million ($1.25 million). The funds will be used to advance the filing of an IND with the FDA by the end of 2022, to secure ...
Importantly, no subjects in the IDCT treatment groups have experienced serious treatment-emergent adverse events (TEAEs). ...
” KORSUVA™ (difelikefalin) injection was approved by the U.S. Food and Drug Administration in August 2021 for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. ...
Xarelto is the only Factor Xa anticoagulant FDA approved for pediatric patients and offers a flexible weight-based dosing Xarelto is available in both oral tablet and liquid suspension formulations for use in appropriate children less than 18 years of age Convenient liquid formulation advances standard of care for children; alleviates administration challenges found with ...
ByBayer AG
Camurus AB (NASDAQ STO: CAMX) today announced that its US licensee Braeburn has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for its updated New Drug Application (NDA) for Brixadi (buprenorphine) extended-release injections for the treatment of opioid use disorder. The CRL is a result of continued quality related ...
Ocular diseases previously thought untreatable are being treated quite successfully using biologics. We explore some of the treatments that are helping patients suffering from ophthalmic diseases. ...
Camurus (NASDAQ STO: CAMX) today announces that the European Medicines Agency (EMA) has accepted the company’s submission of a Type II variation application for Buvidal (buprenorphine) prolonged release injection to include treatment of chronic pain. “We are pleased that the review procedure has been initiated. ...